BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
You may also be interested in...
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.
Bristol Myers Squibb has launched three new first-in-class drugs this year – Opdualag, Camzyos and Sotyktu – and investors are closely watching the early momentum.
Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.